% alzhub.org library filter
% Source: https://alzhub.org/research?category=treatments&author=Andersen+SW
% 3 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{mintun2021-33720637,
  author  = {Mintun, M. A. and Lo, A. C. and Duggan Evans, C. and Wessels, A. M. and Ardayfio, P. A. and Andersen, S. W. and Shcherbinin, S. and Sparks, J. and others},
  title   = {{Donanemab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2021},
  doi     = {10.1056/nejmoa2100708},
  pmid    = {33720637},
  url     = {https://doi.org/10.1056/nejmoa2100708}
}

@article{wessels2020-31764959,
  author  = {Wessels, A. M. and Tariot, P. N. and Zimmer, J. A. and Selzler, K. J. and Bragg, S. M. and Andersen, S. W. and Landry, J. and Krull, J. H. and others},
  title   = {{Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials}},
  journal = {JAMA neurology},
  year    = {2020},
  doi     = {10.1001/jamaneurol.2019.3988},
  pmid    = {31764959},
  url     = {https://doi.org/10.1001/jamaneurol.2019.3988}
}

@article{shcherbinin2022-36094645,
  author  = {Shcherbinin, S. and Evans, C. D. and Lu, M. and Andersen, S. W. and Pontecorvo, M. J. and Willis, B. A. and Gueorguieva, I. and Hauck, P. M. and others},
  title   = {{Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.2793},
  pmid    = {36094645},
  url     = {https://doi.org/10.1001/jamaneurol.2022.2793}
}